Salute e Benessere

Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Andrew Obenshain as Chief Executive Officer (“CEO”) of the Company. Mr. Obenshain will also join the Company’s Board of Directors. He succeeds...
Nasdaq GlobeNewswire
01/10/2025

H.I.G. Capital Completes the Acquisition of France Workwear

Fabrice Shoshany, CEO of France Workwear, stated: "We are proud to join the H.I.G. family and grateful for their confidence in our strategy and commitment to our future. This partnership marks the start of a new chapter for France Workwear – one where we will strengthen our leadership in textile rental services, broaden our focus on innovation and sustainability, and continue to deliver exceptional value to our clients, partners, and employees across and beyond France. We are already…
PR Newswire
01/10/2025

SKINGRAPHICA: World First Luxury Skincare For Skinart

Unlike most skincare, which is not designed for the altered structure and pigment of tattooed skin, SKINGRAPHICA uses targeted, stage-specific formulations. Tattoos live in the dermis, and general skincare often contains ingredients that are not Ink-Safe™. These include strong resurfacing acids, high-strength retinoids, and harsh peels, which can thin the skin, accelerate cell turnover, and blur or mute tattoo color. SKINGRAPHICA avoids these harsh, ink-compromising actives, engineering every…
PR Newswire
01/10/2025

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental…

If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from multinational Phase III study in children aged 4 to 11 years with APDSPDUFA target action date of January 31, 2026Leiden, the Netherlands, October 1, 2025:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced...
Nasdaq GlobeNewswire
01/10/2025

TCL Unveils TCL ECORA™: A Game-Changing Material Made from Upcycled Ceramic…

Shane Lee, General Manager of TCL's Design Innovation Center, said: "Recycled ceramic has never been used in the consumer electronics industry, so TCL ECORA™ is totally unique. This eco-friendly solution enhances our products' performance and builds on our TCLGreen initiatives, empowering consumers to live healthier, more comfortable and eco-conscious lives." Shane Lee, General Manager of TCL's Design Innovation Center, said: "Recycled ceramic has never been used in the consumer…
PR Newswire
01/10/2025

HPV-Positive Oropharyngeal Cancer Market Poised for Strong Growth by 2034…

HPV+ Oropharyngeal Cancer Market Summary HPV+ Oropharyngeal Cancer Market Summary Discover the HPV+ oropharyngeal cancer new treatment @New Treatments for HPV+ Oropharyngeal Cancer Key Factors Driving the Growth of the HPV+ Oropharyngeal Cancer Market Rising incidence and shifting epidemiology The proportion of oropharyngeal cancers caused by HPV has increased substantially over the past two decades in many countries, producing a growing patient pool specifically labeled as…
PR Newswire
30/09/2025

University Health Network's Princess Margaret Cancer Centre Enters Research…

Upright radiotherapy is gaining renewed global attention for its potential to make advanced treatments such as proton therapy more accessible. By positioning the patient upright and rotating them in front of a fixed beam, rather than rotating a large, costly gantry, the approach has the potential to significantly reduce complexity and cost. Early research and patient feedback also suggest that upright treatment may offer a more comfortable and connected experience. Upright radiotherapy is...
PR Newswire
30/09/2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral…

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring1 1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines2,3Remibrutinib also in clinical development for ...
Nasdaq GlobeNewswire
30/09/2025

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

PARIS and CAMBRIDGE, Mass., Sept.30, 2025(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date ...
Nasdaq GlobeNewswire
30/09/2025

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman…

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of DirectorsNantes, September 30, 2025, 7:30 p.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE)held its Annual General Meeting today in Paris and welcomed the participation of shareholders in this key moment for the company’s future. The shareholders who voted on the resolutions represented approximately 56% of OSE’s share capital and more than 62% of the voting rights...
Nasdaq GlobeNewswire
30/09/2025

AB Science announces a slight delay in the publication of its 2025 half-year…

PRESS RELEASEAB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2025 HALF-YEAR FINANCIAL REPORTTHE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2025 ON OCTOBER 10, 2025, AT THE LATESTParis, September 30 2025, 6.30pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its financial report for the first half of 2025, initially scheduled for 30 September 2025, to give the auditors time to complete their...
Nasdaq GlobeNewswire
30/09/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from September 22nd to September 26th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1122/09/2025 ...
Nasdaq GlobeNewswire
30/09/2025

Oxurion maakt halfjaarresultaten 2025 bekend

Leuven, BELGIË – 30 September 2025 – 18:00 CET Oxurion NV (Euronext Brussel: OXUR) (de Vennootschap), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, maakt vandaag haar financiële en zakelijke update bekend voor het half jaar dat eindigde op 30 juni 2025. Het halfjaarverslag is beschikbaar in de rubriek 'Investeerders' op de website van de…
Actusnews Wire
30/09/2025

Oxurion Publishes First Half 2025 Results

Leuven, BELGIUM – September 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, published today its financial and business update for the six-month period ending June 30, 2025. The half-year report is available in the 'Investors' section of the Company's website and can also be…
Actusnews Wire
30/09/2025

Major Wellbeing Organization Selects Aino’s SaaS Platform

Aino Health AB (publ) has signed an agreement—facilitated through its occupational health collaboration partner Työterveys Aalto Occupational Health Care —with a leading wellbeing sector organization, covering 11,000 employees. The implementation of Aino’s SaaS platform is planned to begin within 2025, aiming to enhance proactive work ability management and employee well-being across the organization. “We are honored to support this organization in their mission to improve employee...
Nasdaq GlobeNewswire
30/09/2025

Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal…

, Sept.30, 2025(GLOBE NEWSWIRE) -- Dr. Rahul Patel of Icahn School of Medicine at Mount Sinai presented “alfapump®: Totally Implantable Peritoneal Drain Pump with Urinary Bladder Drainage” Ghent, Belgium – September 30, 2025–Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that thealfa pump® System was featured in a podium...
Nasdaq GlobeNewswire
30/09/2025

Eternal Beauty Holdings Unveils 2025 China Perfume & Fragrance White Paper at…

Decoding China's "Scent Economy": New Pathways for Growth DecodingChina's"Scent Economy": New Pathways for Growth Amid global market fluctuations,China'sfragrance market stands out as a global growth engine and local resilience benchmark. It consistently outpaced other beauty categories in growth, demonstrating market stability. Male consumers and Gen Z from lower-tier cities are gradually unlocking their consumption potential, injecting fresh momentum into the market…
PR Newswire
30/09/2025

Change in Board’s Composition

Press Release Paris – September 30, 2025- EUROAPI today announces that, in line with best governance’s practices, and following his appointment as Recipharm’s Chief Financial Officer, effective October 1 st, 2025, Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025.The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be...
Nasdaq GlobeNewswire
30/09/2025

Total number of shares and voting rights in Zealand Pharma as of September 30…

Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025Copenhagen, Denmark, September 30, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in…
Nasdaq GlobeNewswire
30/09/2025

Dialysis Equipment Market to Reach US$ 19.14 billion by 2031 at CAGR of 5.9% |…

Technology is becoming the principal engine of growth, where AI-powered monitoring systems enable patients to have real-time monitoring of their dialysis cycle, automatically adjusting treatment parameters to optimize fluid removal and electrolyte balance. Portable and home-based dialysis devices have enhanced patient autonomy by reducing the need for dialysis center visits and have also provided flexibility in treatment schedules. This is a paradigm shift in the global landscape of the dialysis…
PR Newswire
30/09/2025

RTLS Market For Healthcare Is Projected To Reach US$10.66 Billion By 2031, at…

Valued at US$3.27 billion in 2024, the real-time location systems market for healthcare is projected to reach US$10.66 billion by 2031, registering a strong CAGR of 18.6% (2025–2031). This growth is driven by increasing demand for patient and asset tracking, workflow optimization, and enhanced safety measures in healthcare facilities. Valued at US$3.27 billionin 2024, thereal-time location systems market for healthcareis projected to reach US$10.66 billionby 2031, registering a...
PR Newswire
30/09/2025

/C O R R E C T I O N -- Elton John AIDS Foundation/

NEW YORK, Sept. 30, 2025 /PRNewswire/ -- The Elton John AIDS Foundation today announced an ambitious expansion of The Rocket Fund, raising its campaign goal to $200 million to accelerate transformative HIV solutions for marginalized communities. The expanded funding will close critical gaps left by global cuts and tackle the stigma that continues to block access to lifesaving care. NEW YORK , Sept. 30, 2025 /PRNewswire/ -- The Elton John AIDS Foundation today announced an ambitious...
PR Newswire
30/09/2025

Pressure Monitoring Devices Market Outlook: Increasing Remote Patient Monitoring…

Check valuable insights in the Pressure Monitoring Devices Market report. You can easily get a sample PDF of the report - https://www.businessmarketinsights.com/sample/BMIPUB00031722 Check valuable insights in thePressure Monitoring Devices Market report.You can easily get a sample PDF of the report -https://www.businessmarketinsights.com/sample/BMIPUB00031722 Technology is becoming the principal engine of growth, where continuous blood monitoring technologies are stimulating growth...
PR Newswire
30/09/2025

Active Pharmaceutical Ingredients (API) Market to Reach USD 445.7 Billion by…

Market Highlights Market Highlights Key Regional Markets Leading the Way The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/active-pharmaceutical-ingredients-market-1099/request-sample Free Sample Includes: Technological & Industry Momentum Why This Matters for Executives & Investors? The API market is evolving into a multi-billion-dollar value engine for...
PR Newswire
30/09/2025
Altri  Comunicati